Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial.

Katharina LechnerClemens von SchackyJohannes ScherrElke LorenzMatthias BockBenjamin LechnerBernhard HallerAlexander KrannichMartin HalleRolf WachterAndré DuvinageFrank Edelmann

Published in: Biomedicines (2022)

Blood SFAs were differentially linked to biomarkers and anthropometric markers indicative of a higher-/lower-risk cardiometabolic phenotype in HFpEF patients. Blood SFA warrant further investigation as prognostic markers in HFpEF. One Sentence Summary: In patients with HFpEF, individual circulating blood SFAs were differentially associated with cardiometabolic phenotype and aerobic capacity.

Keyphrases

end stage renal disease
fatty acid
ejection fraction
chronic kidney disease
clinical trial
study protocol
peritoneal dialysis
randomized controlled trial
prognostic factors
phase iii
patient reported outcomes